Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral vaccines - Pharos Biologicals

Drug Profile

Research programme: viral vaccines - Pharos Biologicals

Latest Information Update: 28 Jun 2020

At a glance

  • Originator Pharos Biologicals
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Viral infections

Highest Development Phases

  • No development reported Dengue; Influenza virus infections; Zika virus infection

Most Recent Events

  • 28 Jun 2020 No recent reports of development identified for preclinical development in Zika-virus-infection in USA
  • 28 Jun 2020 No recent reports of development identified for research development in Dengue in USA
  • 28 Jun 2020 No recent reports of development identified for research development in Influenza-virus-infections in USA

Development Overview

Introduction

Pharos Biologicals is developing vaccines for the prevention of flavivirus and influenza infections, using Johns Hopkins University School of Medicine's proprietary lysosome-associated membrane protein (LAMP) DNA vaccine technology and other nano technologies. Preclinical research for Zika virus infection is ongoing in the US, with early research underway for dengue and influenza infections.

The LAMP technology utilises normal cellular mechanisms to enhance the immune response to the vaccine, which is comprised of antigen protein sequences are encoded as an antigen/LAMP chimera construct. The LAMP DNA vaccine is not a live virus vaccine, has a more rapid development time line, delivers the pathogen antigen directly to cell proteins that bring about immunological responses, and is highly stable.

Viral vaccines program is available for licensing (Pharos Biologicals website, May 2016).

As at June 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection in USA, research development in Dengue in USA, research development in Influenza-virus-infections in USA.

Company Agreements

In May 2016, Pharos Biologicals received exclusive worldwide license for a patented Lysosome-Associated Membrane Protein (LAMP) DNA vaccine technology and other nanotechnologies from Johns Hopkins University School of Medicine. Financial details of the deal were not disclosed [1] .

Key Development Milestones

Pharos Biologicals is planning to initiate a phase I clinical trial in patients with Zika virus infection, by the end of 2016 [1] [2] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class DNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Dengue - - No development reported (Research) USA unspecified / unspecified Pharos Biologicals 28 Jun 2020
Influenza virus infections - - No development reported (Research) USA unspecified / unspecified Pharos Biologicals 28 Jun 2020
Zika virus infection - - No development reported (Preclinical) USA unspecified / unspecified Pharos Biologicals 28 Jun 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Pharos Biologicals Originator
Pharos Biologicals Owner
Johns Hopkins University School of Medicine Technology Provider USA

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Pharos Biologicals Viral infections Unspecified - 11 May 2016

Development History

Event Date Update Type Comment
28 Jun 2020 Phase Change - No development reported No recent reports of development identified for preclinical development in Zika-virus-infection in USA Updated 28 Jun 2020
28 Jun 2020 Phase Change - No development reported No recent reports of development identified for research development in Dengue in USA Updated 28 Jun 2020
28 Jun 2020 Phase Change - No development reported No recent reports of development identified for research development in Influenza-virus-infections in USA Updated 28 Jun 2020
11 May 2016 Licensing Status Research programme: viral vaccines - Pharos Biologicals is available for licensing as of 11 May 2016. http://pharosbiologicals.com./ Updated 11 May 2016
02 May 2016 Trial Update Pharos Biologicals plans a phase I trial for Zika virus infections [1] Updated 11 May 2016
02 May 2016 Licensing Status Pharos Biologicals in-licenses Lysosome-Associated Membrane Protein (LAMP) DNA vaccine technology from Johns Hopkins University School of Medicine [1] Updated 05 May 2016
02 May 2016 Phase Change Early research in Dengue and Influenza virus infections in USA (unspecified route) [1] Updated 05 May 2016
02 May 2016 Phase Change - Preclinical Preclinical trials in Zika virus infection in USA (unspecified route) [1] Updated 05 May 2016

References

  1. Pharos Biologicals Conducting Tests of a Novel Zika Vaccine.

    Media Release
  2. Phase 1 study of Zika vaccine in patients with zika infection

    ctiprofile
Back to top